Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN) announced participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 11:00 a.m. EST. The discussion aims to showcase the company's commitment to developing targeted therapies for pediatric cancer. A live audio webcast will be accessible on the company’s website, with an archived version available for 30 days post-event. Day One focuses on addressing critical needs in pediatric cancer treatment, exemplified by their investigational drug candidates, tovorafenib (DAY101) and pimasertib.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:00 a.m. EST.
A live audio webcast of the discussion will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company’s name was inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in South San Francisco. For more information, please visit www.dayonebio.com or find the company on LinkedIn or Twitter.
Contacts:
DAY ONE MEDIA
Laura Cooper, Head of Communications
laura.cooper@dayonebio.com
DAY ONE INVESTORS
Hans Vitzthum, LifeSci Advisors
hans@lifesciadvisors.com
FAQ
What event will Day One Biopharmaceuticals (DAWN) participate in on November 29, 2022?
What time is Day One Biopharmaceuticals' presentation at the Piper Sandler conference?
Where can I watch the webcast of Day One Biopharmaceuticals' fireside chat?
How long will the webcast of the Day One Biopharmaceuticals event be available?
What is the focus of Day One Biopharmaceuticals?
